Clinical trial
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic…
NCT00055861 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00055861 |
|---|---|
| Title | Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer |
| Official title | PHASE 2 STUDY OF BEVACIZUMAB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH ADVANCED BREAST CANCER |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | bevacizumab, docetaxel, laboratory biomarker analysis |
| Enrollment | 27 |
| Start date | Jul 1, 2002 |
| Primary completion | Aug 1, 2006 |
| First posted | Mar 7, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: